Active Studies: Completed Recruitment

01. BLEEDING RISK

Full Study Title: Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

Principal Investigator: Phil Wells

Funding: HSF (Heart and Stroke Foundation of Canada)

Design: Cohort study of VTE (Venous Thromboembolism) patients on anticoagulants to derive a decision rule for bleeding

For more information: NCT00788736 https://clinicaltrials.gov/

Published Abstract: ISTH 2017 - Research and Practice in Thrombosis and Haemostasis: Bleed Risk 

 

02. COBRRA Pilot

Full Study Title: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban

Principal Investigator: Lana Castellucci

Funding: CanVECTOR Pilot

Design: Open-label pilot RCT (randomized clinical trial) comparing bleeding risk with rivaroxaban versus apixaban

For more information: NCT02559856 https://clinicaltrials.gov/

03. PAUSE

Full Study Title: Perioperative Anticoagulant Use for Surgery Evaluation Study

Principal Investigator: Jim Douketis

Funding: CIHR (Canadian Institutes of Health Research), HSF (Heart and Stroke Foundation of Canada)

Design: Prospective cohort study of patients with atrial fibrillation on new oral anticoagulants requiring interruption for elective surgery/procedure; looking to develop a safer perioperative protocol

For more information: NCT02228798 https://clinicaltrials.gov/

 

04. PERIOP 2

Full Study Title: A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin

Principal Investigator: Michael Kovacs

Funding: CIHR (Canadian Institutes of Health Research), Pfizer

Design: Double-blind RCT (randomized clinical trial) of post-procedure bridging with LMWH (low-molecular-weight heparin) versus placebo for patients on long-term warfarin who require temporary interruption of warfarin

For more information: NCT00432796 https://clinicaltrials.gov/

 

05. PEGED

Full Study Title: D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism

Principal Investigator: Clive Kearon

Funding: CIHR (Canadian Institutes of Health Research)

Design: Prospective cohort study to assess a new diagnostic management strategy for suspected pulmonary embolism in outpatients

For more information: NCT02483442 https://clinicaltrials.gov/

06. PREDICTORS

Full Study Title: Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis

Principal Investigators: Gregoire Le Gal

Funding: HSF (Heart and Stroke Foundation of Canada)

Design: Prospective cohort of patients with a history of thrombosis and new symptoms of VTE (venous thromboembolism); evaluating the performance of current clinical decision rules with this population

For more information: NCT02297373 https://clinicaltrials.gov/

 

07. RASET

Full Study Title: Rivaroxaban Anticoagulation for Superficial Vein Thrombosis

Principal Investigator: Clive Kearon

Funding: Bayer

Design: Double-blind RCT (randomized clinical trial) of rivaroxaban versus placebo for treatment of superficial vein thrombosis

For more information: NCT02123524 https://clinicaltrials.gov/

08. RAPS

Full Study Title: Rivaroxaban for Antiphospholipid Antibody Syndrome

Principal Investigators: Mark Crowther, Kimberly Legault

Funding: HSF (Heart and Stroke Foundation of Canada), Bayer

Design: Pilot prospective management study of rivaroxaban for patients with antiphospholipid antibody syndrome

For more information: NCT02116036 https://clinicaltrials.gov/

 

09. STEP-CAT

Full Study Title: Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots

Principal Investigator: Vicky Tagalakis

Funding: Sanofi

Design: Pilot management cohort study involving cancer patients with DVT (deep vein thrombosis) or PE (pulmonary embolism); step down to prophylactic doses of enoxaparin after 3-6 months of full-dose treatment

For more information:NCT02752607 https://clinicaltrials.gov/